登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H22N6O7S2 · 5H2O
化学文摘社编号:
分子量:
636.65
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
SMILES string
[s]1c(nc(c1)\C(=N\OC(C)(C)C(=O)[O-])\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)[O-])C[n+]4ccccc4)N.O.O.O.O.O.[H+]
InChI
1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1
InChI key
NMVPEQXCMGEDNH-TZVUEUGBSA-N
grade
pharmaceutical primary standard
API family
ceftazidime
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
−20°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Ceftazidime pentahydrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Ceftazidime
- Ceftazidime Injection
- Ceftazidime for Injection
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
signalword
Danger
hcodes
Hazard Classifications
Resp. Sens. 1 - Skin Sens. 1
法规信息
涉药品监管产品
此项目有
Ceftazidime
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 45(3), 872-872 (2018)
Kai Ming Chow et al.
Pharmacotherapy, 23(3), 369-373 (2003-03-12)
We reviewed 42 cases of cefepime-induced neurotoxicity and 12 cases of ceftazidime-induced neurotoxicity from the literature and our institution. Clinical characteristics and timing of diagnosis were examined. Common findings were confusion with temporospatial disorientation (96% of patients), myoclonus (33%), and
S Segal-Maurer et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 28(5), 1134-1138 (1999-08-19)
Increasing prevalence of multidrug-resistant gram-negative organisms has led to a rise in clinically significant infections with these organisms and an increasing therapeutic dilemma. We present a case of a neurosurgical patient who developed ventriculoperitoneal shunt-associated ventriculitis due to ceftazidime-resistant Klebsiella
Jason A Roberts et al.
International journal of antimicrobial agents, 29(2), 117-128 (2006-12-13)
Sepsis and nosocomial infections continue to be a significant problem in intensive care, contributing heavily to mortality and prolonged hospital stay. Early and appropriate antibiotic therapy is critical for optimising outcomes. However, the emergence of highly resistant bacteria, coupled with
C P Rains et al.
Drugs, 49(4), 577-617 (1995-04-01)
Ceftazidime is a third generation cephalosporin antibacterial agent which, since its introduction in the early 1980s, has retained a broad spectrum of in vitro antimicrobial activity and clinical utility in serious infections. However, increasing resistance to ceftazidime and other third
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持